Fintel reports that on January 8, 2026, Wolfe Research upgraded their outlook for Elevance Health (NYSE:ELV) from Peer Perform to Outperform.
Analyst Price Forecast Suggests 7.43% Upside
As of December 20, 2025, the average one-year price target for Elevance Health is $393.94/share. The forecasts range from a low of $323.20 to a high of $516.02. The average price target represents an increase of 7.43% from its latest reported closing price of $366.69 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Elevance Health is 176,691MM, a decrease of 9.31%. The projected annual non-GAAP EPS is 47.43.
What is the Fund Sentiment?
There are 2,503 funds or institutions reporting positions in Elevance Health. This is an decrease of 178 owner(s) or 6.64% in the last quarter. Average portfolio weight of all funds dedicated to ELV is 0.40%, an increase of 1.49%. Total shares owned by institutions decreased in the last three months by 3.81% to 232,124K shares. 
The put/call ratio of ELV is 0.64, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 7,265K shares representing 3.27% ownership of the company. In its prior filing, the firm reported owning 7,059K shares , representing an increase of 2.84%. The firm decreased its portfolio allocation in ELV by 17.88% over the last quarter.
Wellington Management Group Llp holds 6,621K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 6,318K shares , representing an increase of 4.58%. The firm decreased its portfolio allocation in ELV by 88.12% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 6,413K shares representing 2.89% ownership of the company. In its prior filing, the firm reported owning 6,324K shares , representing an increase of 1.40%. The firm decreased its portfolio allocation in ELV by 19.43% over the last quarter.
Price T Rowe Associates holds 5,839K shares representing 2.63% ownership of the company. In its prior filing, the firm reported owning 8,085K shares , representing a decrease of 38.47%. The firm decreased its portfolio allocation in ELV by 43.34% over the last quarter.
Sanders Capital holds 5,769K shares representing 2.60% ownership of the company. In its prior filing, the firm reported owning 5,825K shares , representing a decrease of 0.98%. The firm decreased its portfolio allocation in ELV by 24.61% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
